EGFR overexpression is not common in patients with head and neck cancer. Cell lines are not representative for the clinical situation in this indication
Oncotarget2018Vol. 9(48), pp. 28965–28975
Citations Over TimeTop 10% of 2018 papers
Sami S. Khaznadar, Martin Khan, Elke Schmid, Sebastian Gebhart, Eva-Tessina Becker, Thomas Krahn, Oliver von Ahsen
Abstract
Cell lines are not representative of the clinical situation in HNSCC. Larger studies should investigate whether patient subgroups with activating EGFR mutations or overexpression can be identified.
Related Papers
- → Kinetics of Inhibitor Cycling Underlie Therapeutic Disparities between EGFR-Driven Lung and Brain Cancers(2012)54 cited
- → Upregulated interleukin‐6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma(2015)53 cited
- → Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts(2011)14 cited
- → Erlotinib-induced complete response in a patient with epidermal growth factor receptor wild-type lung adenocarcinoma after chemotherapy failure: a case report(2014)6 cited
- → In Silico Identification of Novel Erlotinib Analogues Against Epidermal Growth Factor Receptor(2016)3 cited